Haleon CEO Targets China and India as Growth Engines Amid Global Expansion Push

Haleon, the global consumer health company formed from the spin-off of GlaxoSmithKline’s consumer division, is placing renewed emphasis on China and India as central pillars of its international growth plan. The CEO highlighted that both nations represent high-potential markets with growing middle-class populations and increasing health awareness, positioning them as strategic priorities for product launches and distribution enhancements. The company is targeting a compound annual growth rate of 8% in Asia-Pacific markets over the next five years, with India and China expected to contribute over 60% of that growth. This follows recent investments totaling $210 million in manufacturing and logistics infrastructure across the region, including two new facilities in southern India and an upgraded plant in Guangzhou, China. These upgrades aim to improve supply chain resilience and reduce time-to-market for over-the-counter and wellness products. The expansion comes as Haleon’s stock, trading under the ticker HLE, has outperformed the broader consumer staples sector (XLP) by 14% year-to-date, reflecting investor confidence in its international strategy. Competitors such as Johnson & Johnson (JNJ) and Pfizer (PFE) are also increasing their focus on Asia, with JNJ reporting a 12% increase in Asia-Pacific revenue in the last fiscal quarter. This regional competition is likely to intensify as consumer health spending in India and China is projected to exceed $350 billion by 2030, according to industry estimates. Market analysts note that Haleon’s China-India focus could influence capital allocation trends across the consumer health and healthcare sectors, particularly in emerging markets. Investors are closely monitoring the company’s progress in regulatory approvals, distribution partnerships, and localized product development as key success indicators.